DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Graft Versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023" drug pipelines to their offering.
Graft versus Host Disease (GVHD) Market Insights, Epidemiology and Market Forecast 2023 report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023).
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). Our forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92%, 2.73% and 2.71% for U.S., EU5 and Japan, respectively, from 2013 to 2023.
The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). For the United States, as per our forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 1.00% and 4.14%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 1.00% and 4.14%, respectively, by the end of the year 2023.
The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. estimates suggest that the global forecasted market size of Graft Versus Host Disease (GVHD) shall increase at a CAGR of 5.47% from 2013 to 2023.
Key Topics Covered:
- Graft Versus Host Disease (GVHD)
- Disease Definition
- Disease Types
- Acute GvHD
- Chronic GvHD
- Grades of GvHD
- Risk Factors for GVHD
- Epidemiology and Patient Population
- Key Points
- Current Unmet Needs of Graft Versus Host Disease (GVHD)
- Marketed Drugs
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/mxt5cs/graft_versus_host